Renal Toxicity of Anticancer Agents Targeting HER2 and EGFR

Overview

Journal J Nephrol

Publisher Springer

Specialty Nephrology

Date 2015 Sep 6

PMID 26341657

Citations 18

Authors

Laura Cosmai

Maurizio Gallieni

Camillo Porta

Affiliations

Soon will be listed here.

Abstract

EGFR and HER2 are found overexpressed and/or activated in many different human malignancies (e.g. breast and colon cancer), and a number of drugs specifically targeting these two tyrosine kinases have been developed over the years as anticancer agents. In the present review, the renal safety profile of presently available agents targeting either HER2 or EGFR will be discussed, together with the peculiarities related to their clinical use in patients with impaired renal function, or even in dialysis. Indeed, even though renal toxicity is not so common with these agents, it may nevertheless happen, especially when these agents are combined with traditional chemotherapeutic agents. As a whole, kidney impairment or dialysis should not be regarded per se as reasons not to administer or to stop an active anti-HER or anti-EGFR anticancer treatment, especially given the possibility of significantly improving the life expectancy of many cancer patients with the use of these agents.

Citing Articles

Toxicity Profile of eBAT, a Bispecific Ligand-Targeted Toxin Directed to EGFR and uPAR, in Mice and a Clinical Dog Model.

Dicovitsky R, Schappa J, Schulte A, Lang H, Kuerbitz E, Roberts S Toxins (Basel). 2024; 16(9).

PMID: 39330834 PMC: 11436214. DOI: 10.3390/toxins16090376.

Nephrotoxicity of targeted therapy used to treat lung cancer.

Li Q, Lin J, Hao G, Xie A, Liu S, Tang B Front Immunol. 2024; 15:1369118.

PMID: 39026680 PMC: 11254629. DOI: 10.3389/fimmu.2024.1369118.

The renal damage and mechanisms relevant to antitumoral drugs.

Tang J, Yang N, Pan S, Ren P, Chen M, Jin J Front Oncol. 2023; 13:1331671.

PMID: 38148845 PMC: 10749913. DOI: 10.3389/fonc.2023.1331671.

Pyrotinib-associated acute kidney injury: A case report.

Miao K, Zhang L, Si X Cancer Innov. 2023; 1(4):344-347.

PMID: 38089087 PMC: 10686108. DOI: 10.1002/cai2.38.

Tumor Markers as Predictors of Acute Kidney Injury Incidence and Staging of the Muscle-Invasive Bladder Cancer Receiving Chemoradiation Therapy.

Mirsya Warli S, Febrian Prapiska F, Siregar D, Seja I World J Oncol. 2023; 14(5):423-429.

PMID: 37869246 PMC: 10588499. DOI: 10.14740/wjon1676.

References

Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C . Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009; 361(10):958-67. DOI: 10.1056/NEJMoa0904554. View

Del Conte A, Minatel E, Schinella D, Baresic T, Basso S, Lumachi F . Complete metabolic remission with Gefitinib in a hemodialysis patient with bone metastases from non-small cell lung cancer. Anticancer Res. 2014; 34(1):319-22. View

Porta C, Cosmai L, Gallieni M, Pedrazzoli P, Malberti F . Renal effects of targeted anticancer therapies. Nat Rev Nephrol. 2015; 11(6):354-70. DOI: 10.1038/nrneph.2015.15. View

Verma S, Miles D, Gianni L, Krop I, Welslau M, Baselga J . Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012; 367(19):1783-91. PMC: 5125250. DOI: 10.1056/NEJMoa1209124. View

Sequist L, Yang J, Yamamoto N, OByrne K, Hirsh V, Mok T . Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013; 31(27):3327-34. DOI: 10.1200/JCO.2012.44.2806. View

Cao Y, Liu L, Liao C, Tan A, Gao F . Meta-analysis of incidence and risk of hypokalemia with cetuximab-based therapy for advanced cancer. Cancer Chemother Pharmacol. 2009; 66(1):37-42. DOI: 10.1007/s00280-009-1131-5. View

Fornaro L, Lucchesi M, Caparello C, Vasile E, Caponi S, Ginocchi L . Anti-HER agents in gastric cancer: from bench to bedside. Nat Rev Gastroenterol Hepatol. 2011; 8(7):369-83. DOI: 10.1038/nrgastro.2011.81. View

Dimke H, van der Wijst J, Alexander T, Meijer I, Mulder G, Goor H . Effects of the EGFR Inhibitor Erlotinib on Magnesium Handling. J Am Soc Nephrol. 2010; 21(8):1309-16. PMC: 2938592. DOI: 10.1681/ASN.2009111153. View

GOLDENBERG M . Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther. 1999; 21(2):309-18. DOI: 10.1016/S0149-2918(00)88288-0. View

10.

Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S . Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a.... Lancet. 2010; 375(9712):377-84. DOI: 10.1016/S0140-6736(09)61964-4. View

11.

Tetu B, Brisson J . Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy. Cancer. 1994; 73(9):2359-65. DOI: 10.1002/1097-0142(19940501)73:9<2359::aid-cncr2820730919>3.0.co;2-9. View

12.

Costa A, Tejpar S, Prenen H, Van Cutsem E . Hypomagnesaemia and targeted anti-epidermal growth factor receptor (EGFR) agents. Target Oncol. 2011; 6(4):227-33. DOI: 10.1007/s11523-011-0200-y. View

13.

Tiel Groenestege W, Thebault S, van der Wijst J, van den Berg D, Janssen R, Tejpar S . Impaired basolateral sorting of pro-EGF causes isolated recessive renal hypomagnesemia. J Clin Invest. 2007; 117(8):2260-7. PMC: 1934557. DOI: 10.1172/JCI31680. View

14.

Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M . Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011; 365(14):1273-83. PMC: 3268553. DOI: 10.1056/NEJMoa0910383. View

15.

Rossi A, Maione P, Del Gaizo F, Guerriero C, Castaldo V, Gridelli C . Safety profile of gefitinib in advanced non-small cell lung cancer elderly patients with chronic renal failure: two clinical cases. Lung Cancer. 2005; 47(3):421-3. DOI: 10.1016/j.lungcan.2004.09.002. View

16.

Cao Y, Liao C, Tan A, Liu L, Gao F . Meta-analysis of incidence and risk of hypomagnesemia with cetuximab for advanced cancer. Chemotherapy. 2010; 56(6):459-65. DOI: 10.1159/000321011. View

17.

Gianni L, Pienkowski T, Im Y, Roman L, Tseng L, Liu M . Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2011; 13(1):25-32. DOI: 10.1016/S1470-2045(11)70336-9. View

18.

Chen P, Wang L, Li H, Liu B, Zou Z . Incidence and risk of hypomagnesemia in advanced cancer patients treated with cetuximab: A meta-analysis. Oncol Lett. 2013; 5(6):1915-1920. PMC: 3700916. DOI: 10.3892/ol.2013.1301. View

19.

Kim E, Hirsh V, Mok T, Socinski M, Gervais R, Wu Y . Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet. 2008; 372(9652):1809-18. DOI: 10.1016/S0140-6736(08)61758-4. View

20.

Carlomagno C, Perrone F, Gallo C, De Laurentiis M, Lauria R, Morabito A . c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol. 1996; 14(10):2702-8. DOI: 10.1200/JCO.1996.14.10.2702. View